2
|
Orabi MAA, Abouelela ME, Darwish FMM, Abdelkader MSA, Elsadek BEM, Al Awadh AA, Alshahrani MM, Alhasaniah AH, Aldabaan N, Abdelhamid RA. Ceiba pentandra ethyl acetate extract improves doxorubicin antitumor outcomes against chemically induced liver cancer in rat model: a study supported by UHPLC-Q-TOF-MS/MS identification of the bioactive phytomolecules. Front Pharmacol 2024; 15:1337910. [PMID: 38370475 PMCID: PMC10871037 DOI: 10.3389/fphar.2024.1337910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Accepted: 01/19/2024] [Indexed: 02/20/2024] Open
Abstract
Hepatocellular carcinoma (HCC) is a prevalent cancer worldwide. Late-stage detection, ineffective treatments, and tumor recurrence contribute to the low survival rate of the HCC. Conventional chemotherapeutic drugs, like doxorubicin (DOX), are associated with severe side effects, limited effectiveness, and tumor resistance. To improve therapeutic outcomes and minimize these drawbacks, combination therapy with natural drugs is being researched. Herein, we assessed the antitumor efficacy of Ceiba pentandra ethyl acetate extract alone and in combination with DOX against diethylnitrosamine (DENA)-induced HCC in rats. Our in vivo study significantly revealed improvement in the liver-function biochemical markers (ALT, AST, GGT, and ALP), the tumor marker (AFP-L3), and the histopathological features of the treated groups. A UHPLC-Q-TOF-MS/MS analysis of the Ceiba pentandra ethyl acetate extract enabled the identification of fifty phytomolecules. Among these are the dietary flavonoids known to have anticancer, anti-inflammatory, and antioxidant qualities: protocatechuic acid, procyanidin B2, epicatechin, rutin, quercitrin, quercetin, kaempferol, naringenin, and apigenin. Our findings highlight C. pentandra as an affordable source of phytochemicals with possible chemosensitizing effects, which could be an intriguing candidate for the development of liver cancer therapy, particularly in combination with chemotherapeutic drugs.
Collapse
Affiliation(s)
- Mohamed A. A. Orabi
- Department of Pharmacognosy, College of Pharmacy, Najran University, Najran, Saudi Arabia
| | - Mohamed E. Abouelela
- Department of Pharmacognosy, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt
| | - Faten M. M. Darwish
- Department of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut, Egypt
| | | | - Bakheet E. M. Elsadek
- Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt
| | - Ahmed Abdullah Al Awadh
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia
| | - Mohammed Merae Alshahrani
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia
| | - Abdulaziz Hassan Alhasaniah
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia
| | - Nayef Aldabaan
- Department of Pharmacology, College of Pharmacy, Najran University, Najran, Saudi Arabia
| | - Reda A. Abdelhamid
- Department of Pharmacognosy, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt
| |
Collapse
|
7
|
Lee JB, Zhou S, Chiang M, Zang X, Kim TH, Kagan L. Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically-based pharmacokinetic modeling. Biopharm Drug Dispos 2020; 41:192-205. [PMID: 32342986 DOI: 10.1002/bdd.2229] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Revised: 04/18/2020] [Accepted: 04/22/2020] [Indexed: 12/12/2022]
Abstract
The aim of the study was to develop a physiologically-based pharmacokinetic (PBPK) model to describe and predict whole-body disposition of doxorubicin following intravenous administration. The PBPK model was established using previously published data in mice and included 10 tissue compartments: lungs, heart, brain, muscle, kidneys, pancreas, intestine, liver, spleen, adipose tissue, and plasma. Individual tissues were described by either perfusion-limited or permeability-limited models. All parameters were simultaneously estimated and the final model was able to describe murine data with good precision. The model was used for predicting doxorubicin disposition in rats, rabbits, dogs, and humans using interspecies scaling approaches and was qualified using plasma and tissue observed data. Reasonable prediction of the plasma pharmacokinetics and tissue distribution was achieved across all species. In conclusion, the PBPK model developed based on a rich dataset obtained from mice, was able to reasonably predict the disposition of doxorubicin in other preclinical species and humans. Applicability of the model for special populations, such as patients with hepatic impairment, was also demonstrated. The proposed model will be a valuable tool for optimization of exposure profiles of doxorubicin in human patients.
Collapse
Affiliation(s)
- Jong Bong Lee
- Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, NJ, 08854, USA
| | - Simon Zhou
- Translational Development and Clinical Pharmacology, Celgene Corporation, NJ, 07920, USA
| | - Manting Chiang
- Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, NJ, 08854, USA.,Center of Excellence for Pharmaceutical Translational Research and Education, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, NJ, 08854, USA
| | - Xiaowei Zang
- Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, NJ, 08854, USA
| | - Tae Hwan Kim
- College of Pharmacy, Daegu Catholic University, Gyeongsan, Republic of Korea, 38430
| | - Leonid Kagan
- Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, NJ, 08854, USA.,Center of Excellence for Pharmaceutical Translational Research and Education, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, NJ, 08854, USA
| |
Collapse
|
9
|
Moulin M, Piquereau J, Mateo P, Fortin D, Rucker-Martin C, Gressette M, Lefebvre F, Gresikova M, Solgadi A, Veksler V, Garnier A, Ventura-Clapier R. Sexual Dimorphism of Doxorubicin-Mediated Cardiotoxicity. Circ Heart Fail 2015; 8:98-108. [DOI: 10.1161/circheartfailure.114.001180] [Citation(s) in RCA: 77] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Background—
Cardiovascular diseases are the major cause of mortality among both men and women with a lower incidence in women before menopause. The clinical use of doxorubicin, widely used as an antineoplastic agent, is markedly hampered by severe cardiotoxicity. Even if there is a significant sex difference in incidence of cardiovascular disease at the adult stage, it is not known whether a difference in doxorubicin-related cardiotoxicity between men and women also exists. The objective of this work was to explore the cardiac side effects of doxorubicin in adult rats and decipher whether signaling pathways involved in cardiac toxicity differ between sexes.
Methods and Results—
After 7 weeks of doxorubicin (2 mg/kg per week), males developed major signs of cardiomyopathy with cardiac atrophy, reduced left ventricular ejection fraction and 50% mortality. In contrast, no female died and their left ventricular ejection fraction was only moderately affected. Surprisingly, neither global oxidation levels nor the antioxidant response nor the apoptosis signaling pathways were altered by doxorubicin. However, the level of total adenosine monophosphate–activated protein kinase was severely decreased only in males. Moreover, markers of mitochondrial biogenesis and cardiolipin content were strongly reduced only in males. To analyze the onset of the pathology, maximal oxygen consumption rate of left ventricular permeabilized fibers after 4 weeks of treatment was reduced only in doxorubicin-treated males.
Conclusions—
Altogether, these results clearly evidence sex differences in doxorubicin toxicity. Cardiac mitochondrial dysfunction and adenosine monophosphate–activated protein kinase seem as critical sites of sex differences in cardiotoxicity as evidenced by significant statistical interactions between sex and treatment effects.
Collapse
Affiliation(s)
- Maryline Moulin
- From the INSERM UMR-S 769, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., M.G., F.L., M.G., V.V., A.G., R.V.-C.); IPSIT-IFR141 Université de Paris-Sud, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., C.R.-M., M.G., F.L., M.G., A.S., V.V., A.G., R.V.-C.); INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (C.R.-M.); and IPSIT-IFR141 Service d’Analyse des Médicaments et Métabolites, Châtenay-Malabry, France (A.S.)
| | - Jérôme Piquereau
- From the INSERM UMR-S 769, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., M.G., F.L., M.G., V.V., A.G., R.V.-C.); IPSIT-IFR141 Université de Paris-Sud, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., C.R.-M., M.G., F.L., M.G., A.S., V.V., A.G., R.V.-C.); INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (C.R.-M.); and IPSIT-IFR141 Service d’Analyse des Médicaments et Métabolites, Châtenay-Malabry, France (A.S.)
| | - Philippe Mateo
- From the INSERM UMR-S 769, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., M.G., F.L., M.G., V.V., A.G., R.V.-C.); IPSIT-IFR141 Université de Paris-Sud, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., C.R.-M., M.G., F.L., M.G., A.S., V.V., A.G., R.V.-C.); INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (C.R.-M.); and IPSIT-IFR141 Service d’Analyse des Médicaments et Métabolites, Châtenay-Malabry, France (A.S.)
| | - Dominique Fortin
- From the INSERM UMR-S 769, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., M.G., F.L., M.G., V.V., A.G., R.V.-C.); IPSIT-IFR141 Université de Paris-Sud, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., C.R.-M., M.G., F.L., M.G., A.S., V.V., A.G., R.V.-C.); INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (C.R.-M.); and IPSIT-IFR141 Service d’Analyse des Médicaments et Métabolites, Châtenay-Malabry, France (A.S.)
| | - Catherine Rucker-Martin
- From the INSERM UMR-S 769, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., M.G., F.L., M.G., V.V., A.G., R.V.-C.); IPSIT-IFR141 Université de Paris-Sud, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., C.R.-M., M.G., F.L., M.G., A.S., V.V., A.G., R.V.-C.); INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (C.R.-M.); and IPSIT-IFR141 Service d’Analyse des Médicaments et Métabolites, Châtenay-Malabry, France (A.S.)
| | - Mélanie Gressette
- From the INSERM UMR-S 769, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., M.G., F.L., M.G., V.V., A.G., R.V.-C.); IPSIT-IFR141 Université de Paris-Sud, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., C.R.-M., M.G., F.L., M.G., A.S., V.V., A.G., R.V.-C.); INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (C.R.-M.); and IPSIT-IFR141 Service d’Analyse des Médicaments et Métabolites, Châtenay-Malabry, France (A.S.)
| | - Florence Lefebvre
- From the INSERM UMR-S 769, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., M.G., F.L., M.G., V.V., A.G., R.V.-C.); IPSIT-IFR141 Université de Paris-Sud, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., C.R.-M., M.G., F.L., M.G., A.S., V.V., A.G., R.V.-C.); INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (C.R.-M.); and IPSIT-IFR141 Service d’Analyse des Médicaments et Métabolites, Châtenay-Malabry, France (A.S.)
| | - Milada Gresikova
- From the INSERM UMR-S 769, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., M.G., F.L., M.G., V.V., A.G., R.V.-C.); IPSIT-IFR141 Université de Paris-Sud, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., C.R.-M., M.G., F.L., M.G., A.S., V.V., A.G., R.V.-C.); INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (C.R.-M.); and IPSIT-IFR141 Service d’Analyse des Médicaments et Métabolites, Châtenay-Malabry, France (A.S.)
| | - Audrey Solgadi
- From the INSERM UMR-S 769, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., M.G., F.L., M.G., V.V., A.G., R.V.-C.); IPSIT-IFR141 Université de Paris-Sud, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., C.R.-M., M.G., F.L., M.G., A.S., V.V., A.G., R.V.-C.); INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (C.R.-M.); and IPSIT-IFR141 Service d’Analyse des Médicaments et Métabolites, Châtenay-Malabry, France (A.S.)
| | - Vladimir Veksler
- From the INSERM UMR-S 769, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., M.G., F.L., M.G., V.V., A.G., R.V.-C.); IPSIT-IFR141 Université de Paris-Sud, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., C.R.-M., M.G., F.L., M.G., A.S., V.V., A.G., R.V.-C.); INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (C.R.-M.); and IPSIT-IFR141 Service d’Analyse des Médicaments et Métabolites, Châtenay-Malabry, France (A.S.)
| | - Anne Garnier
- From the INSERM UMR-S 769, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., M.G., F.L., M.G., V.V., A.G., R.V.-C.); IPSIT-IFR141 Université de Paris-Sud, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., C.R.-M., M.G., F.L., M.G., A.S., V.V., A.G., R.V.-C.); INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (C.R.-M.); and IPSIT-IFR141 Service d’Analyse des Médicaments et Métabolites, Châtenay-Malabry, France (A.S.)
| | - Renée Ventura-Clapier
- From the INSERM UMR-S 769, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., M.G., F.L., M.G., V.V., A.G., R.V.-C.); IPSIT-IFR141 Université de Paris-Sud, Châtenay-Malabry, France (M.M., J.P., P.M., D.F., C.R.-M., M.G., F.L., M.G., A.S., V.V., A.G., R.V.-C.); INSERM UMR-S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (C.R.-M.); and IPSIT-IFR141 Service d’Analyse des Médicaments et Métabolites, Châtenay-Malabry, France (A.S.)
| |
Collapse
|